Your browser doesn't support javascript.
loading
MASCC/ISOO clinical practice statement: Current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation.
Raber-Durlacher, Judith E; Zadik, Yehuda; Treister, Nathaniel S; Stempler, Noa; Bruno, Julia S; Epstein, Joel B; Elad, Sharon.
Afiliação
  • Raber-Durlacher JE; Department of Oral Medicine, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands. j.raber.durlacher@acta.nl.
  • Zadik Y; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. j.raber.durlacher@acta.nl.
  • Treister NS; Department of Oral Medicine and Saligman Clinics, Faculty of Dental Medicine, The Hebrew University of Jerusalem, and Hadassah Medical Center, Jerusalem, Israel.
  • Stempler N; Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA.
  • Bruno JS; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
  • Epstein JB; Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel.
  • Elad S; Molecular Oncology Center-Hospital Sírio-Libanês, São Paulo, Brazil.
Support Care Cancer ; 32(8): 550, 2024 Jul 25.
Article em En | MEDLINE | ID: mdl-39048882
ABSTRACT

PURPOSE:

A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians, which concentrates on practical information needed for the management of oral complications of cancer patients. This CPS is focused on the current understanding of controversies that may arise while providing basic oral care in hemato-oncology patients and hematopoietic cell transplantation recipients (HCT). The CPS will summarize and elucidate controversies that have appeared in the literature and professional discussions.

METHODS:

This CPS was developed based on a critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets to generate a short manual about the best standard of care.

RESULTS:

Controversies about the use of chlorhexidine (CHX) oral rinse, mechanical dental plaque removal procedures, the need for toothbrush replacement during phases of low blood cell counts, and the use of lidocaine mouthwash for oral pain were identified and discussed. Consensus about the best standard of care was outlined.

CONCLUSION:

The following ratifications are applicable for oral care in hemato-oncology patients and patients undergoing HCT (1) CHX may reduce the risk of oral infections, although it was not found to reduce the risk of oral mucositis. (2) Toothbrushing and proficient interproximal cleaning should not be discouraged during HCT. (3) Toothbrushes do not need to be replaced daily and are preferred over cleansing swabs. (4) Lidocaine rinse, swish and spit, may be considered to palliate oral mucosal pain if applied in a certain manner.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article